Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients.

Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients. Abstract Text:

J Atzpodien,K Terfloth,M Fluck,M Reitz,J Atzpodien,K Terfloth,M Fluck,M Reitz,J Atzpodien,K Terfloth,M Fluck,M Reitz,J Atzpodien,K Terfloth,M Fluck,M Reitz,

To evaluate the efficacy of cisplatin, gemcitabine, and treosulfan (CGT) in 91 patients with pretreated relapsed AJCC stage IV cutaneous malignant melanoma. Patients in relapse after first-, second-, or third-line therapy received 40 mg m(-2) intravenous (i.v.) cisplatin, 1000 mg m(-2) i.v. gemcitabine, and 2500 mg m(-2) i.v. treosulfan on days 1 and 8. Cisplatin, gemcitabine, and treosulfan therapy was repeated every 5 weeks until progression of disease occurred. A maximum of 11 CGT cycles (mean, two cycles) was administered per patient. Four patients (4%) showed a partial response; 15 (17%) patients had stable disease; and 72 (79%) patients progressed upon first re-evaluation. Overall survival of all 91 patients was 6 months (2-year survival rate, 7%). Patients with partial remission or stable disease exhibited a median overall survival of 11 months (2-year survival rate, 36%), while patients with disease progression upon first re-evaluation had a median overall survival of 5 months (2-year survival rate, 0%). Treatment with CGT was efficient in one-fifth of the pretreated relapsed stage IV melanoma patients achieving disease stabilisation or partial remission with prolonged but limited survival.British Journal of Cancer (2007) 97, 1329-1332. doi:10.1038/sj.bjc.6604045 www.bjcancer.com Published online 30 October 2007.

Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients. Publishing Authors By Initials

J Atzpodien,K Terfloth,M Fluck,M Reitz,J Atzpodien,K Terfloth,M Fluck,M Reitz,J Atzpodien,K Terfloth,M Fluck,M Reitz,J Atzpodien,K Terfloth,M Fluck,M Reitz,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: British journal of cancer

VOLUME: 97

Page Numbers: 1329-32

Journal Abbreviation:

ISSN: 0007-0920

DAY: 30

MONTH: 10

YEAR: 2007

Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 370635

Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients.

AFFILIATION: [1] 1Fachklinik Hornheide an der Westfälischen Wilhelms-Universität Münster, Dorbaumstr. 300, Münster 48157, Germany [2] 2Europäisches Institut für Tumor Immunologie und Prävention (EUTIP), Bad Honnef, Germany.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Br J Cancer

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients Related Publications

• "One-and-half ventricle" cardiac transplantation for complex congenital heart disease.
• 8-(Heteroaryl)phenalkyl-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-ones as opioid receptor modulators.
• A cross-sectional study of bone turnover markers in healthy premenopausal women.
• A review of present methods in the early diagnosis of bronchogenic carcinoma.
• An alteration of human immunodeficiency virus gp41 leads to reduced CCR5 dependence and CD4 independence.
• Antibiotic effects of circulin against certain gram-negative plant pathogens.
• Basic principles governing animals and their treatment.
• Can the ice-water test predict the outcome of intradetrusor injections of botulinum toxin in patients with neurogenic bladder dysfunction?
• Cisplatin, gemcitabine and treosulfan is effective in chemotherapy-pretreated relapsed stage IV uveal melanoma patients.
• Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients.
• Competitive exclusion of a worldwide invasive pest by a native. Quantifying competition between two phytophagous insects on two host plant species.
• Design, synthesis, and biological evaluation of pyrazinones containing novel P1 needles as inhibitors of TF/VIIa.
• Ecology. Invasion of the whiteflies.
• Editorial comment on: effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve.
• Filling the pipeline for neglected diseases: creation of a medicinal chemistry-centric international drug discovery institute [iDDi].
• Fractional polynomials in a new metastatic renal carcinoma continuous prognostic index involving histology, laboratory, and clinical predictors.
• Heart lung transplantation.
• Metabolic fate of the antipsychotic agent, mazapertine, in man--API-MS and MS/MS identification of urinary metabolites.
• Novel tetrahydro-beta-carboline-1-carboxylic acids as inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2).
• Peripheral Blood Neutrophils as Independent Immunologic Predictor of Response and Long-Term Survival upon Immunotherapy in Metastatic Renal-Cell Carcinoma.
• Pneumatic paracorporeal ventricular assist device in infants and children: initial Stanford experience.
• Safety assessment of dairy microorganisms: Bacterial taxonomy.
• The neuronal sortilin-related receptor gene SORL1 and late-onset Alzheimer's disease.
• Twenty-year survivors of heart transplantation at stanford university.